In vemurafenib-resistant non BRAF-mutated melanoma cells, sorafenib increased intracellular ROS levels and induced ferroptosis, thereby enhancing the sensitivity of resistant tumors to vemurafenib. The gene discussed is BRAF; the disease is melanoma.